AAN: Isradipine Offers No Benefit in Parkinson Disease

AAN: Isradipine Offers No Benefit in Parkinson Disease
HealthDay News — Isradipine does not appear to slow progression of disability in patients with de novo Parkinson disease (PD), according to a study presented at the annual meeting of the American Academy of Neurology, held from May 4 to 10 in Philadelphia. Tanya Simuni, MD, from the Northwestern University Feinberg School of Medicine in Chicago, conducted a 36-month study ... read more
Source: Neurology AdvisorPublished on 2019-05-14By Haymarket Media